timothy sykes logo
RXRX Stock Dips As Traders Weigh Cash Runway And Heavy Losses Thumbnail
G Google News

RXRX Stock Dips As Traders Weigh Cash Runway And Heavy Losses

BRYCE TUOHEY•UPDATED OCT. 8, 2026, 12:32 PM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Recursion Pharmaceuticals Inc. stocks have been trading down by -10.42 percent after bearish sentiment over slowing pipeline progress.

Key Takeaways

  • RXRX is pulling back after a failed push above $5, with shares now trading around the low-$4s and testing recent support.
  • The intraday RXRX tape shows tight consolidation near $3.80–$3.90, signaling indecision and shrinking volatility after a sharp two-day slide.
  • Recursion Pharmaceuticals Inc. is generating about $74.3M in annual revenue, but profit margins remain deeply negative as the company spends heavily on R&D.
  • RXRX holds more than $545M in cash against modest debt, giving Recursion Pharmaceuticals Inc. a sizable runway despite steep quarterly losses.
  • Traders are tracking RXRX near-term levels around $3.70 support and $4.80–$5 resistance as potential momentum triggers.

Candlestick Chart

Live Update At 12:32:19 EDT: On Thursday, October 08, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending down by -10.42%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RXRX is a classic high-cash, high-burn story in the biotech–AI crossover space. Recursion Pharmaceuticals Inc. posted roughly $74.3M in revenue over the last year, but the company is still deep in the red. Profit margins are ugly across the board, with EBIT margin near -958% and profit margin around -951%. That tells traders RXRX is nowhere near break-even.

At the same time, RXRX has a surprisingly strong balance sheet for a small-cap biotech-style name. Recursion Pharmaceuticals Inc. reports about $545.7M in cash and short-term investments, versus total debt that is only a fraction of that. Current and quick ratios around 5 and 4.6 show RXRX can cover its near-term bills several times over.

More Breaking News

The flip side is the burn. In the latest quarter, RXRX posted a net loss of about $131M and operating cash outflow near $106M. Free cash flow was roughly -$107.9M. For traders, that means Recursion Pharmaceuticals Inc. has runway, but the clock is ticking. Dilution, partnerships, or cost cuts stay on the table longer term, and the chart will usually sniff that out early.

Why Traders Are Watching RXRX Price Action

RXRX has been building a base in the mid-$3s to low-$4s, then tried to break out and failed. On the daily chart, Recursion Pharmaceuticals Inc. climbed from around $3.19 on 2026/09/16 to a high near $5.19 on 2026/10/06. That’s a strong, near-60% push in a few weeks. But what matters now is the rejection.

After spiking to $4.93–$5.19 on 2026/10/05–06, RXRX rolled over. The stock closed at $4.63 on 2026/10/06, slipped to $4.27 on 2026/10/07, and slid again to $3.83 on 2026/10/08. That’s a quick, clean fade from breakout levels back toward the prior range. For short-term traders, Recursion Pharmaceuticals Inc. is now a textbook failed breakout with overhead resistance stacked between $4.80 and $5.

The intraday chart adds detail. RXRX opened heavy near $4.19 and bled lower most of the regular session, then went flat. From late morning through midday, the 5‑minute candles on Recursion Pharmaceuticals Inc. hovered around $3.83–$3.90 with tight ranges and small wicks. That type of action screams consolidation after a selloff. Momentum traders see RXRX in “decision mode” — either setting up for a bounce back toward $4.20–$4.50 or gearing up for a crack under $3.70 support.

For now, volume and range are contracting. When that coil breaks, experienced traders in RXRX will be ready to react, not predict.

Conclusion

RXRX is exactly the kind of tricky biotech name that punishes lazy trading. Recursion Pharmaceuticals Inc. has a big story, big losses, and a big cash pile. The fundamentals show a company still in build-out mode: revenue is tiny relative to its valuation, margins are deeply negative, and quarterly cash burn tops $100M. But the balance sheet for RXRX is strong enough that a sudden liquidity crisis is not the near-term worry.

On the technical side, the tape is clearer. RXRX ripped from the low-$3s to just over $5, then failed hard and is now sitting back near the prior base. Support for Recursion Pharmaceuticals Inc. sits in the $3.70–$3.80 zone; resistance lines up around $4.20 first, then $4.80–$5. Short-term traders are watching to see which side breaks with volume. A clean move through either level can offer opportunity, but only for those who respect risk.

As Tim Sykes likes to say, “Trading isn’t about being right, it’s about managing risk when you’re wrong.” As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. RXRX demands that mindset. Recursion Pharmaceuticals Inc. is a speculative, story-driven stock, and the only real edge for traders here is discipline — tight risk, clear levels, and zero hesitation to cut losses fast when the chart turns against you.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”